| 2026-02-05 |
详情>>
股本变动：
变动后总股本4647.14万股
|
| 2026-02-05 |
详情>>
业绩披露：
2026年三季报(累计)每股收益2.47美元,归母净利润1.17亿美元,同比去年增长7.07%
|
| 2026-02-05 |
财报披露：
美东时间 2026-02-05 盘前发布财报
|
| 2025-11-10 |
详情>>
内部人交易：
KROLL MARK W股份增加1400.00股
|
| 2025-11-06 |
详情>>
业绩披露：
2026年中报每股收益1.52美元,归母净利润7271.50万美元,同比去年增长0.71%
|
| 2025-08-07 |
详情>>
业绩披露：
2026年一季报每股收益0.71美元,归母净利润3403.10万美元,同比去年增长-11.32%
|
| 2025-06-06 |
股东大会：
将于2025-07-24召开股东大会
会议内容 ▼▲
- 1.To elect nine director nominees named in this Proxy Statement for one-year terms expiring at the 2026 Annual Meeting of Shareholders (Item 1);
2.To approve, on an advisory basis, the compensation of our named executive officers (Item 2);
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 28, 2026 (Item 3);
4.To transact such other business as may properly come before the meeting.
|
| 2025-05-21 |
详情>>
业绩披露：
2023年年报每股收益2.27美元,归母净利润1.15亿美元,同比去年增长166.05%
|
| 2025-05-21 |
详情>>
业绩披露：
2025年年报每股收益3.33美元,归母净利润1.68亿美元,同比去年增长42.64%
|
| 2025-02-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益2.16美元,归母净利润1.10亿美元,同比去年增长12.87%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年中报每股收益1.30美元,归母净利润6595.00万美元,同比去年增长24.26%
|
| 2024-11-07 |
详情>>
业绩披露：
2025年中报每股收益1.42美元,归母净利润7220.40万美元,同比去年增长9.48%
|
| 2024-08-08 |
详情>>
业绩披露：
2025年一季报每股收益0.75美元,归母净利润3837.30万美元,同比去年增长-6.5%
|
| 2024-06-07 |
股东大会：
将于2024-07-25召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees named in the proxy statement to one-year terms expiring in 2025;
2.To approve, on an advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 29, 2025;
4.To transact such other business as may properly come before the meeting.
|
| 2024-05-20 |
详情>>
业绩披露：
2024年年报每股收益2.32美元,归母净利润1.18亿美元,同比去年增长1.87%
|
| 2024-02-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益1.92美元,归母净利润9719.10万美元,同比去年增长12.99%
|
| 2023-06-16 |
股东大会：
将于2023-08-04召开股东大会
会议内容 ▼▲
- 1.To elect the eight director nominees named in the proxy statement to one-year terms expiring in 2024;
2.To approve, on an advisory basis, the compensation of our named executive officers;
3.To approve, on an advisory basis, the frequency of future advisory votes on the compensation of our named executive officers;
4.To approve an amendment and restatement of the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan;
5.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 30, 2024;
6.To transact such other business as may properly come before the meeting.
|
| 2022-06-17 |
股东大会：
将于2022-08-05召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees named in the proxy statement to one-year terms expiring in 2023;
2.To approve, on an advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending April 1, 2023;
4.To transact such other business as may properly come before the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-17 |
股东大会：
将于2021-08-06召开股东大会
会议内容 ▼▲
- 1.To elect the six director nominees named in the proxy statement to one-year terms expiring in 2022;
2.To approve, on an advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending April 2, 2022;
4.To transact such other business as may properly come before the meeting.
|
| 2020-06-30 |
股东大会：
将于2020-07-21召开股东大会
会议内容 ▼▲
- 1.To elect the four director nominees named in the proxy statement to one-year terms expiring in 2021;
2.To approve, on an advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending April 3, 2021;
4.To transact such other business as may properly come before the meeting.
|
| 2019-06-12 |
股东大会：
将于2019-07-25召开股东大会
会议内容 ▼▲
- 1.Election of Mark W. Kroll, Claire Pomeroy and Ellen M. Zane as Class II directors
2.Approval, on an advisory basis, of our named executive officers’ compensation
3.Ratification of our independent registered public accounting firm for fiscal
4.Approval of amendments to our Restated Articles of Organization to provide for the annual election of directors
5.Approval of Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan
|
| 2018-06-12 |
股东大会：
将于2018-07-26召开股东大会
会议内容 ▼▲
- 1.To elect the three director nominees named in the proxy statement as Class I directors with terms expiring in 2021;
2.To approve, on an advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 30, 2019;
4.To approve amendments to the Company’s Restated Articles of Organization and By-Laws to reduce certain super-majority voting requirements to a majority voting standard;
5.To consider a shareholder proposal to elect each director annually, if properly presented at the meeting;
6.To transact such other business as may properly come before the meeting.
|
| 2017-06-12 |
股东大会：
将于2017-07-27召开股东大会
会议内容 ▼▲
- 1.To elect two directors as more fully described in the accompanying Proxy Statement;
2.To consider and act upon an advisory vote regarding the compensation of our Named Officers;
3.To consider and act upon an advisory vote on the frequency of future advisory votes on the compensation of the Company's Named Officers;
4.Shareholder proposal to recommend changes to certain voting requirements;
5.To ratify Ernst & Young LLP as our independent registered public accounting firm to audit the consolidated financial statements of the Company and its subsidiaries for the fiscal year ending March 31, 2018;
6.To consider and act upon any other business which may properly come before the Meeting.
|
| 2016-06-10 |
股东大会：
将于2016-07-21召开股东大会
会议内容 ▼▲
- 1.To elect three (3) directors as more fully described in the accompanying Proxy Statement.
2.To consider and act upon an advisory vote regarding the compensation of our named executive officers.
3.To approve an Amendment to Haemonetics Corporation's 2007 Employee Stock Purchase Plan.
4.To approve the adoption of the Worldwide Executive Bonus Plan.
5.To ratify Ernst & Young LLP as our independent registered public accounting firm to audit the consolidated financial statements of the Company and its subsidiaries for the fiscal year ending April 1, 2017.
6.To consider and act upon any other business which may properly come before the Meeting.
|
| 2015-06-11 |
股东大会：
将于2015-07-21召开股东大会
会议内容 ▼▲
- 1.To elect three (3) directors as more fully described in the accompanying Proxy Statement.
2.To consider and act upon an advisory vote regarding the compensation of our named executive officers.
3.To ratify Ernst & Young LLP as independent registered public accounting firm to audit the consolidated financial statements of the Company and its subsidiaries for the fiscal year ended April 2, 2016.
4.To consider and act upon any other business which may properly come before the meeting.
|